HK Stock Market Move | Innovative drug concept stocks fell across the board; rate hike expectations weigh on the innovative drug sector; Citi expects medical insurance price cuts to be moderate and manageable.

date
10:05 20/11/2026
avatar
GMT Eight
Innovative drug concept stocks fell across the board. As of press time, GenScript Biotech (01548) fell 6.17% to HK$28.3; 3SBio (01530) fell 4.78% to HK$12.56; Innovent Biologics (01801) fell 4.68% to HK$81.45; InnoCare Pharma (09969) fell 3.80% to HK$10.13.
Innovative drug concept stocks fell across the board. As of press time, GENSCRIPT B-1K (01548) fell 6.17% to HK$28.3; 3SBIO (01530) fell 4.78% to HK$12.56; INNOVENT BIO (01801) fell 4.68% to HK$81.45; InnoCare Pharma (09969) fell 3.80% to HK$10.13. On the news front, US inflation has continued to exceed expectations, and the Federal Reserve's policy path has tightened again. The Chicago Fed president said on Thursday that all policy options are on the table at the Fed's next policy meeting and that the possibility of a single rate hike larger than usual has not been ruled out. As a rate-sensitive long-duration asset, innovative drugs have underperformed the market under the influence of rate hike expectations. Citi issued a research report stating that it noted JW Therapeutics' CAR-T product relma-cel entered the national medical insurance directory at a price of RMB288,600, a reduction of 77.6%. The commercial insurance innovative drug directory newly included 12 drugs, including CAR-T. Although most post-negotiation drug prices have not yet been disclosed, most pharmaceutical companies the bank has contacted have guided that the price cuts are moderate and manageable; the new directory will take effect on January 1, 2027, and the bank will monitor the final tender prices after implementation.